For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA5138Ua&default-theme=true
RNS Number : 5138U AstraZeneca PLC 01 August 2022
1 August 2022 17:00 BST
Revised stock exchange announcement due to a formatting issue with the
original announcement published at 1505 today, 1 August 2022. There have been
no changes to the underlying information within the release.
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 29 July 2022 awards of
AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin,
Executive Director and Chief Financial Officer. Each ADS represents one half
of an Ordinary Share of $0.25 in the Company.
In accordance with the Agreement and Plan of Merger between the Company and
Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's in-flight share awards
granted by Alexion were converted to awards over AstraZeneca ADSs under the
AstraZeneca Global Restricted Stock Plan at the time of closing of the Alexion
acquisition. The awards that vested on 29 July 2022 replaced in-flight Alexion
awards originally granted to Dr Sarin between February 2019 and February 2021
under the Alexion 2017 Incentive Plan.
Following the withholding of shares to satisfy certain tax obligations arising
on vesting, 67,523 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the awards was
US$66.72, being the closing price on the last trading day preceding the
vesting.
Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Aradhana Sarin
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4i Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument AstraZeneca PLC American Depositary Shares
Identification code
CUSIP: 046353108
b) Nature of the transaction Acquisition of AstraZeneca PLC American Depository Shares pursuant to a
vesting under the Global Restricted Stock Plan
c) Price(s) and volume(s)
Price(s) Volume(s)
0 67,523
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
e) Date of the transaction 29 July 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
29 July 2022
f)
Place of the transaction
Outside a trading venue
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .
Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUAVVRUUUWRAR